Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.53
-0.0900-2.49%
Post-market: 3.530.00000.00%19:30 EDT
Volume:1.04M
Turnover:3.64M
Market Cap:110.45M
PE:-0.85
High:3.61
Open:3.58
Low:3.35
Close:3.62
52wk High:49.25
52wk Low:3.35
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.35
T/O Rate:5.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.50
PE(LYR):-1.24

Loading ...

Summit Therapeutics secures major AstraZeneca equity partnership

TIPRANKS
·
Sep 29

Summit Therapeutics price target raised to $43 from $40 at Citi

TIPRANKS
·
Sep 29

Chimeric Therapeutics Seeks ASX Quotation for 29.3 Million New Shares

TIPRANKS
·
Sep 29

Thalia Therapeutics Secures Chinese Patent for Lead AML Drug miRisten

TIPRANKS
·
Sep 29

Top Executive Makes Bold Insider Move at Damora Therapeutics

TIPRANKS
·
Sep 29

Addex Therapeutics Earnings Call Highlights Pipeline Upside

TIPRANKS
·
Sep 29

Closing Bell Movers: Summit Therapeutics jumps on AstraZeneca investment

TIPRANKS
·
Sep 29

Defence Therapeutics Advances Oncology Strategy and Tightens Leadership Alignment

TIPRANKS
·
Sep 29

Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment

TIPRANKS
·
Sep 29

Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

TIPRANKS
·
Sep 29

AstraZeneca makes $2B equity investment in Summit Therapeutics

TIPRANKS
·
Sep 29

Tempest Therapeutics Strengthens Governance and CAR-T Partnership Framework

TIPRANKS
·
Sep 29

Mirum Therapeutics Reaffirmed as Top Pick as Analyst Hikes Price Target to $195 on Strong Clinical and Regulatory Wins

TIPRANKS
·
Sep 29

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

GlobeNewswire
·
Sep 28

Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial

TIPRANKS
·
Sep 28

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

GlobeNewswire
·
Sep 28

Press Release: Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Dow Jones
·
Sep 28

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

GlobeNewswire
·
Sep 28

Coiled Therapeutics Director Increases Stake as Precision Oncology Pipeline Advances

TIPRANKS
·
Sep 28